Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

88.65 +1.42 (+1.63%)
Streaming Delayed Price Updated: 12:19 PM EDT, Oct 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,792,934
Open 87.72
Bid (Size) 88.64 (3)
Ask (Size) 88.66 (3)
Prev. Close 87.23
Today's Range 87.61 - 89.22
52wk Range 62.07 - 88.39
Shares Outstanding 1,253,809,440
Dividend Yield 3.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Absurdly Cheap Stocks That Pay High Dividends
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets

Performance

YTD
+6.50%
+6.50%
1 Month
+5.55%
+5.55%
3 Month
+20.61%
+20.61%
6 Month
+32.16%
+32.16%
1 Year
+13.44%
+13.44%

More News

Read More
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts
Via Benzinga
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Via Benzinga
Will GILEAD SCIENCES INC breakout?
Via Chartmill
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Via Benzinga
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
Via Talk Markets
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
News Is Noise
Via Talk Markets
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
Top 4 Health Care Stocks That May Keep You Up At Night
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.